Song Wei, Tang Lin, Xu Yumei, Sun Qian, Yang Fang, Guan Xiaoxiang
Department of Medical Oncology, Jinling Hospital, Southern Medical University, Guangzhou, 510515, China.
Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002, China.
J Exp Clin Cancer Res. 2017 Jun 5;36(1):75. doi: 10.1186/s13046-017-0545-x.
Increasing evidence has indicated an important role for estrogen receptor beta 1 (ERβ1) in breast cancer. However, the role of ERβ1 in the metastasis of androgen receptor (AR)-positive triple-negative breast cancer (TNBC) and the underlying mechanisms are still unknown.
Stable ERβ1-expressing TNBC cell lines were generated for this study. We detected the abilities of cell migration and invasion by wound-healing and transwell assays and the expression of E-cadherin and N-cadherin by quantitative RT-PCR (qRT-PCR) and western blotting assays in TNBC cell lines. Chromatin immunoprecipitation (ChIP) analysis was performed to assess the effect of AR on ERβ1 promoter. Tumor metastasis was evaluated in vivo using a lung metastasis mouse model. Lastly, immunohistochemical expression of ERβ1 in TNBC tissues was analyzed and correlated with clinicopathological features.
ERβ1 suppressed the invasion and migration abilities of AR-positive TNBC cells and induced the downregulation of ZEB1. ZEB1 overexpression abrogated the increase in E-cadherin expression and the decrease in N-cadherin expression modulated by ERβ1. A lung metastasis mouse model showed that the incidence of metastasis was lower in ERβ1-expressing TNBC cells. Further, AR activation increased the anti-metastatic effect of ERβ1 in AR-positive TNBC cells, which accelerated ERβ1 transcription by functioning as a transcription factor that bound to the promoter of ERβ1. No significant change was observed in AR expression induced by ERβ1. Immunohistochemistry (IHC) analysis of TNBC clinical samples showed that ERβ1 and AR were positive in 31.7% and 23.2% of samples, respectively. ERβ1 expression was negatively correlated with ZEB1 expression and lymph node metastasis, and positively correlated with the expression of AR and E-cadherin.
Our findings suggested a potential role of ERβ1 in metastasis of AR-positive TNBC and provided novel insights into the mechanism of action of ERβ1 and the possible relationship between ERβ1 and AR.
越来越多的证据表明雌激素受体β1(ERβ1)在乳腺癌中发挥重要作用。然而,ERβ1在雄激素受体(AR)阳性三阴性乳腺癌(TNBC)转移中的作用及其潜在机制仍不清楚。
本研究构建了稳定表达ERβ1的TNBC细胞系。我们通过伤口愈合实验和Transwell实验检测TNBC细胞系的细胞迁移和侵袭能力,并通过定量逆转录聚合酶链反应(qRT-PCR)和蛋白质免疫印迹实验检测E-钙黏蛋白和N-钙黏蛋白的表达。进行染色质免疫沉淀(ChIP)分析以评估AR对ERβ1启动子的影响。使用肺转移小鼠模型在体内评估肿瘤转移情况。最后,分析TNBC组织中ERβ1的免疫组化表达,并将其与临床病理特征相关联。
ERβ1抑制AR阳性TNBC细胞的侵袭和迁移能力,并诱导ZEB1表达下调。ZEB1过表达消除了ERβ1调节的E-钙黏蛋白表达增加和N-钙黏蛋白表达减少。肺转移小鼠模型显示,表达ERβ1的TNBC细胞转移发生率较低。此外,AR激活增强了ERβ1在AR阳性TNBC细胞中的抗转移作用,AR作为转录因子与ERβ1启动子结合,加速了ERβ1转录。ERβ1诱导的AR表达未观察到显著变化。TNBC临床样本的免疫组织化学(IHC)分析显示,分别有31.7%和23.2%的样本ERβ1和AR呈阳性。ERβ1表达与ZEB1表达和淋巴结转移呈负相关,与AR和E-钙黏蛋白表达呈正相关。
我们的研究结果表明ERβ1在AR阳性TNBC转移中具有潜在作用,并为ERβ1的作用机制以及ERβ1与AR之间可能的关系提供了新的见解。